| Editor's Note: This is the last issue of Fierce Biotech in 2024. Starting tomorrow, the Fierce team will be taking a break for the holidays. Fierce Biotech will be back in your inbox on Jan. 2, but be sure to visit the website for the latest news until then. We hope you have a great holiday season and a happy New Year. |
|
Tuesday, January 14, 2025 | 10am ET / 7am PT This webinar highlights the FDA’s discussion paper on health equity in medical devices, investments in inclusive product design and clinical trials, and provider programs educating patients about managing chronic conditions. Register now and discover strategies for fostering equitable access to quality care and improving outcomes for diverse populations.
|
|
Today’s Big NewsDec 23, 2024 |
|
Wednesday, January 15, 2025 | 11am ET / 8am PT Discover how next-gen Protein A resins and multi-column chromatography can help biomanufacturers optimize costs, enhance purification efficiency, and improve productivity. Learn practical strategies and explore real-world case studies showcasing advanced solutions for scalable, high-throughput processes. Register now.
|
|
| By James Waldron From the conference circuit to the Nasdaq trading floor, we run down some of the highlights from Fierce Biotech's coverage this year. |
|
|
|
By Gabrielle Masson For the end of this year, Fierce Biotech is taking the opportunity to reflect on trends emerging from 2024’s reporting. And readers have made it easy for us—it’s clear what kind of story drew the most interest. |
By James Waldron After a year that saw Ikena Oncology trim back its workforce and pipeline, the oncology biotech thinks it’s found a sustainable path forward via a merger into privately owned immunology company Inmagene Biopharmaceuticals. |
By Nick Paul Taylor Rapt Therapeutics has charted a new course following the implosion of its lead program, agreeing to pay $35 million for a long-acting challenger to Novartis and Roche’s Xolair. |
|
Tuesday, January 21, 2025 | 11am ET / 8am PT In today’s fast-paced and uncertain landscape, pharmaceutical manufacturers face complex challenges that demand agile and integrated planning across all business functions. Join us for an exclusive webinar on how to leverage Integrated Business Planning (IBP) to enable a more connected, data-driven approach to planning. Register now.
|
|
By James Waldron Sanofi is handing SK bioscience 50 million euros ($52 million) to take their next-gen pneumococcal conjugate vaccine program into phase 3. |
By James Waldron Phase 2 trial data will continue to be the name of the game when it comes to VC investments into biopharma in 2025, according to PitchBook. |
By Darren Incorvaia A turbulent month at Applied Therapeutics is being capped off with the departure of CEO and chair Shoshana Shendelman, Ph.D., mere days after she and the company were named in a proposed class action lawsuit. |
By Gabrielle Masson Galectin Therapeutics’ stock has halved since the company revealed its investigational drug failed to significantly reduce enlarged veins for people with liver scarring. |
By Darren Incorvaia Clinical research firm Javara has laid off staff as part of a restructuring, a spokesperson confirmed to Fierce Biotech in an email. |
By Eric Sagonowsky For many readers, the topics featured in this year’s roundup of top stories won’t come as much of a surprise. Look no further than our top two stories of the year, and you’ll see that the GLP-1 craze and Big Pharma layoffs took center stage in 2024. |
By Noah Tong,Emma Beavins Both chambers of Congress passed legislation to fund the government on Friday night. |
Fierce podcastsDon’t miss an episode |
| | This week on "Podnosis," we explore how teaching kids social-emotional skills early can transform their lifelong wellbeing. |
|
|---|
|
|
|
Tuesday, January 28, 2025 | 11am ET / 8am PT This webinar explores how AI-powered solutions simplify complex literature management tasks, enabling faster, more accurate insights for pharmaceutical research and drug development. Register now.
|
|
| WhitepaperWe interviewed 14 R&D biopharma leaders on the critical success factors for building a Best Practice R&D organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
